InvestorsHub Logo
Followers 7
Posts 299
Boards Moderated 0
Alias Born 01/07/2010

Re: None

Tuesday, 01/03/2017 5:50:21 PM

Tuesday, January 03, 2017 5:50:21 PM

Post# of 461967
Bit nervous that Rett is the 1st indication A2-73 will complete p3 on. Rett/children, I suppose, present a very different histopathology than AZ. AZ is an affliction correlated to aging and broken myelin sheath from impaired oligodendrocytes - A2-73 fixes this. I can see the commonality with MS.
No clue when it comes to Rett. Even if Rett shares the same cause, the impairment may be due to an epigenetic factor to overcome and probably requires treatment further upstream. Are we expecting A2-73 to overcome mutations or hope it symptomatically treats?
Needless to say failure in Rett would take Anavex back to pennystockland.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News